Autolus Therapeutics (NASDAQ:AUTL) Trading Down 4.4% - Should You Sell?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s share price fell 4.4% during trading on Wednesday . The company traded as low as $2.37 and last traded at $2.38. 955,137 shares traded hands during trading, a decline of 36% from the average session volume of 1,482,567 shares. The stock had previously closed at $2.49.

Wall Street Analysts Forecast Growth

AUTL has been the subject of a number of recent analyst reports. The Goldman Sachs Group upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and upped their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Finally, Needham & Company LLC reissued a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, December 5th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $10.40.

Autolus Therapeutics Price Performance

The business has a 50 day simple moving average of $3.52 and a 200-day simple moving average of $3.82. The stock has a market capitalization of $609.36 million, a price-to-earnings ratio of -1.89 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter last year, the business posted ($0.26) earnings per share. As a group, equities analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently made changes to their positions in AUTL. Wellington Management Group LLP boosted its stake in Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock worth $87,919,000 after purchasing an additional 6,330,392 shares during the period. FMR LLC boosted its position in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company's stock worth $64,519,000 after buying an additional 5,478,706 shares during the period. Renaissance Technologies LLC boosted its position in shares of Autolus Therapeutics by 253.5% during the second quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company's stock worth $3,985,000 after buying an additional 821,156 shares during the period. Erste Asset Management GmbH bought a new position in shares of Autolus Therapeutics during the third quarter worth about $708,000. Finally, GSA Capital Partners LLP acquired a new stake in Autolus Therapeutics in the 3rd quarter valued at approximately $1,082,000. Institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.